Viagra
Product Images NDC 43353-764

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Viagra (NDC 43353-764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25mg (43353 764)

Label for Sildenafil Citrate (Viagra) 25 mg tablets, containing 6 tablets per package. Originally manufactured by Pfizer PGM in Poce Sur Cisse, France, repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. Label includes storage instructions and notes that the medication is Rx only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Viagra 01)

Chemical structure diagram of sildenafil, the active ingredient in Viagra, showing molecular components and bonds, including characteristic heterocyclic rings and functional groups.*

FDA Label Image

Figure 1 (Viagra 02)

A line graph showing systolic blood pressure changes (mmHg) over 24 hours post-dose for Sildenafil 100 mg and a placebo. The x-axis represents time from pre-dose to 24 hours, and the y-axis indicates systolic blood pressure with values ranging approximately from -25 to +15 mmHg. Two lines compare the effects of Sildenafil 100 mg and placebo on systolic blood pressure over time.*

FDA Label Image

Figure 2 (Viagra 03)

Line graph showing change in SBP (mmHg) over time postdose (hours) for two groups: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The graph plots changes in blood pressure from 0 to 8 hours after dosing.*

FDA Label Image

Figure 3 (Viagra 04)

A line graph showing the change in SEP (sexual event profile) metric over time postdose in hours, comparing Doxazosin with placebo and Doxazosin with Sildenafil 50 mg. The y-axis represents change in SEP metric while the x-axis represents time postdose up to 8 hours.*

FDA Label Image

Figure 4 (Viagra 05)

A line graph comparing the change in a variable measured in mmHg over time after dosing (0 to 8 hours). It shows two lines, one for Doxazosin plus Sildenafil 100 mg and one for Doxazosin plus placebo, illustrating their respective changes post dosing.*

FDA Label Image

Figure 5 (Viagra 06)

A pharmacokinetic graph showing plasma concentration (ng/ml) over time post dose (hours) for a commercial tablet. The curve peaks sharply shortly after administration and then gradually declines to near baseline by 24 hours.*

FDA Label Image

Figure 6 (Viagra 07)

A bar chart titled 'Effect of VIAGRA on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint across baseline scores from 0 to 5. The chart includes multiple bars for each baseline score, representing different categories labeled 0 through 5, indicating varying patient response levels.*

FDA Label Image

Figure 6 (Viagra 08)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' depicting the percentage of patients at endpoint on the vertical axis and baseline score on the horizontal axis. Multiple bars at each baseline score represent different categories or groups indicated by a legend with numbers 0 through 5.*

FDA Label Image

Figure 7 (Viagra 09)

A bar chart comparing the percentage of patients reporting improvement across four treatment groups: Placebo, Viagra 25 mg, Viagra 50 mg, and Viagra 100 mg. The vertical axis represents the percentage of patients reporting improvement, ranging from 0% to 100%. The bars show increasing improvement percentages from placebo to the highest Viagra dose.*

FDA Label Image

Logo (Viagra 10)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.